|
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
|
Jul 2023
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Acute leukaemia and myelodysplastic syndromes with chromosomal rearrangement involving 11q23 locus, but not MLL gene
|
Aug 2016
|
J Clin Pathol
|
myelodysplastic syndromes (MDS)
|
|
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults
|
Jul 2014
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Acute myeloid leukemia and myelodysplastic syndromes in older adults
|
Aug 2014
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
|
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
|
Aug 2017
|
Leukemia
|
|
|
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes
|
Feb 2014
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Albumin as a prognostic marker in myelodysplastic syndromes: still relevant after all these years
|
May 2015
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Alcohol use is not a significant contributor to myelodysplastic syndromes
|
Apr 2020
|
Cancer Causes & Control : CCC
|
myelodysplastic syndromes (MDS)
|
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
|
Apr 2023
|
American Journal of Hematology
|
aplastic anemia
|
|
Alemtuzumab in relapsed immune severe aplastic anemia: Long-term results of a phase II study
|
Jun 2023
|
American Journal of Hematology
|
aplastic anemia
|
